Skip to content
OpenCapital
Get started

United Therapeutics UTHR Remodulin — Cost of Sales

Other product segments

Tyvaso DPI
$83.2M+73.0%
Nebulized Tyvaso
$8.6M+1.2%
Orenitram
$7.4M-10.8%
Unituxin
$5M-3.8%
Adcirca
$1M-61.5%

Similar metrics at other companies

LivaNova logo
LIVNNeuromodulation — Cost of Sales
$14.22M+6.2%
Baxter International logo
BAXMedical Products & Therapies — Cost of Sales
$781M+12.5%
Mirum Pharmaceuticals, Inc. logo
MIRMCost of Sales
$28.81M+25.1%
AngioDynamics logo
ANGOMed Device — Cost of sales (exclusive of intangible amortization)
$22.95M+7.3%
Pfizer logo
PFEBiopharma — Cost of Sales
$3.03B+31.1%
Solventum logo
SOLVMedSurg — Cost of Sales
$622M+13.5%

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M—
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity0×—
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's remodulin — cost of sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's remodulin — cost of sales?
United Therapeutics (UTHR) reported remodulin — cost of sales of $16.1M in Q1 2026.
How has United Therapeutics's remodulin — cost of sales changed year-over-year?
United Therapeutics's remodulin — cost of sales increased by 16.7% year-over-year, from $13.8M to $16.1M.
What is the long-term trend for United Therapeutics's remodulin — cost of sales?
Over 4 years (2021 to 2025), United Therapeutics's remodulin — cost of sales has grown at a 6.8% compound annual growth rate (CAGR), from $37.9M to $49.3M.
What does remodulin — cost of sales mean?
Includes the direct costs associated with the manufacturing, packaging, and distribution of a specific pharmaceutical product. This encompasses raw material costs, labor, and overhead directly attributable to the production of the drug. It is a critical component for evaluating the production efficiency and supply chain management of the therapeutic.